-->

Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventFeb 18, 2009View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 17, 2009View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2009View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2009View HTMLDownload DOCDownload PDFDownload XLS
5Annual filing director officer or owner of more than ten percent.Feb 12, 2009View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 12, 2009View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 12, 2009View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 12, 2009View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 5, 2009View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesFeb 5, 2009View HTMLDownload DOCDownload PDF
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Jan 30, 2009View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Jan 30, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 23, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 21, 2009View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJan 20, 2009View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJan 8, 2009View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GJan 7, 2009View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 6, 2009View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-93

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information